Format

Send to

Choose Destination
Trends Biotechnol. 2019 Jan;37(1):9-16. doi: 10.1016/j.tibtech.2018.05.014. Epub 2018 Jun 23.

The Increasingly Human and Profitable Monoclonal Antibody Market.

Author information

1
Biological Systems Engineering Laboratory, Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK; ORCID: https://orcid.org/0000-0002-8592-8304.
2
Biological Systems Engineering Laboratory, Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK; ORCID: https://orcid.or/0000-0001-6183-0292. Electronic address: a.mantalaris@imperial.ac.uk.

Abstract

The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. We summarize the market in terms of therapeutic applications, type and structure of mAbs, dominant companies, manufacturing locations, and emerging markets.

KEYWORDS:

biosimilars; market analysis; monoclonal antibody

PMID:
29945725
DOI:
10.1016/j.tibtech.2018.05.014
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Spiral, Imperial College Digital Repository
Loading ...
Support Center